Cargando…

Genetic Deletion of Sost or Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-induced Bone Disease without Affecting Tumor Growth

Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and concomitant marked suppression of bone formation. Sclerostin (Scl) levels, an osteocyte-derived inhibitor of Wnt/β-catenin signaling, are elevated in MM patient sera and are increased in osteocytes in MM-bearing mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgado-Calle, Jesus, Anderson, Judith, Cregor, Meloney D., Condon, Keith W., Kuhstoss, Stuart A., Plotkin, Lilian I., Bellido, Teresita, Roodman, G. David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699973/ https://www.ncbi.nlm.nih.gov/pubmed/28529307 http://dx.doi.org/10.1038/leu.2017.152

Ejemplares similares

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
por: Sabol, Hayley M., et al.
Publicado: (2022)

Expression of SOST/sclerostin in compressed periodontal ligament cells
por: Ueda, Masae, et al.
Publicado: (2016)

OR29-04 Vitamin D Signaling Prevents Glucocorticoid-Induced Musculoskeletal Tissue Loss And Cardiac Dysfunction By Targeting The Atrogene Pathway
por: Sato, Amy, et al.
Publicado: (2023)

Suppression of Sost/Sclerostin and Dickkopf‐1 Augment Intervertebral Disc Structure in Mice
por: Kroon, Tori, et al.
Publicado: (2022)

Heterozygous deletion of both sclerostin (Sost) and connexin43 (Gja1) genes in mice is not sufficient to impair cortical bone modeling
por: Grimston, Susan K., et al.
Publicado: (2017)

SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury
por: Chang, Jiun C, et al.
Publicado: (2018)

Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo
por: Basha, Genc, et al.
Publicado: (2016)

Expression of Sclerostin in Osteoporotic Fracture Patients Is Associated with DNA Methylation in the CpG Island of the SOST Gene
por: Cao, Yanming, et al.
Publicado: (2019)

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
por: Delgado-Calle, Jesus, et al.
Publicado: (2019)

THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
por: Marino, Silvia, et al.
Publicado: (2023)

DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter
por: Papathanasiou, Ioanna, et al.
Publicado: (2015)

Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
por: Marino, Silvia, et al.
Publicado: (2023)

Reversal of the diabetic bone signature with anabolic therapies in mice
por: Marino, Silvia, et al.
Publicado: (2023)

Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
por: Marino, Silvia, et al.
Publicado: (2023)

Sclerostin
por: Silverman, Stuart L.
Publicado: (2010)

Nrf2 regulates mass accrual and the antioxidant endogenous response in bone differently depending on the sex and age
por: Pellegrini, Gretel Gisela, et al.
Publicado: (2017)

SOST Inhibits Prostate Cancer Invasion
por: Hudson, Bryan D., et al.
Publicado: (2015)

Relationship Between Sclerostin (SOST) Expression and Genetic Loci rs851056, rs1230399 Polymorphisms and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes in Xinjiang
por: Li, Jun, et al.
Publicado: (2021)

Myeloma cells suppress osteoblasts through sclerostin secretion
por: Colucci, S, et al.
Publicado: (2011)

Ex Vivo Organ Cultures as Models to Study Bone Biology
por: Bellido, Teresita, et al.
Publicado: (2020)

A Novel Mutation in SOST Gene Causes Sclerosteosis
por: Alyusuf, Ebtihal Y, et al.
Publicado: (2021)

Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo
por: Bullock, Whitney A., et al.
Publicado: (2019)

Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23
por: Mulcrone, Patrick L., et al.
Publicado: (2020)

Anatomical similarity between the Sost‐knockout mouse and sclerosteosis in humans
por: Schwarze, Uwe Y., et al.
Publicado: (2019)

Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
por: Gerov, Vladimir, et al.
Publicado: (2023)

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
por: van Dinther, Maarten, et al.
Publicado: (2013)

Sost Deficiency does not Alter Bone’s Lacunar or Vascular Porosity in Mice
por: Mosey, Henry, et al.
Publicado: (2017)

SOST Deficiency Aggravates Osteoarthritis in Mice by Promoting Sclerosis of Subchondral Bone
por: Li, Jingyu, et al.
Publicado: (2019)

EFFECT OF PKP ON SERUM SOST IN PATIENTS WITH VERTEaBRAL COMPRESSION FRACTURES
por: WANG, ENZHI, et al.
Publicado: (2020)

Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts
por: Martínez-Gil, Núria, et al.
Publicado: (2021)

PTH Receptor Signaling in Osteocytes Governs Periosteal Bone Formation and Intracortical Remodeling
por: Rhee, Yumie, et al.
Publicado: (2011)

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
por: Toscani, Denise, et al.
Publicado: (2018)

Therapeutic Use of Anti-Sclerostin Antibody in the Treatment of Multiple Myeloma: A Systematic Review
por: Ngomdir, Liza, et al.
Publicado: (2023)

Myeloma bone disease: Pathophysiology and management
por: Silbermann, Rebecca, et al.
Publicado: (2013)

Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner
por: Pellegrini, Gretel G., et al.
Publicado: (2016)

SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease
por: Mason, James J., et al.
Publicado: (2010)

Characterization of the different oligomeric states of the DAN family antagonists SOSTDC1 and SOST
por: Gipson, Gregory R., et al.
Publicado: (2020)

Sclerostin and Vascular Pathophysiology
por: Catalano, Antonino, et al.
Publicado: (2020)

Sclerostin and Cardiovascular Disease
por: Tobias, Jonathan H.
Publicado: (2023)

Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice
por: Kramer, Ina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fu3c4vgdfec95f31mu8km41cpk